Nov 12, 2026, 10:16 UTC
Terumo forecast fiscal 2027 consolidated net profit to fall 36% to ¥87.5 billion, revenue to rise 8% to ¥1.2195 trillion, and operating profit to fall 33% to ¥119 billion, citing shipment suspensions and supply constraints in its aortic and neurovascular businesses.
Source:Nov 5, 2026, 22:15 UTC
Terumo shares rose 257.5 yen to 2,627.5 yen on the 5th as the Democratic Party's gains drew attention to healthcare-related stocks.
Source:Nov 5, 2026, 06:41 UTC
Japanese-listed securities rose on November 5, with SymBio Pharmaceuticals leading the gainers at 71.4%.
Source:Oct 9, 2026, 05:40 UTC
Terumo said the contract termination would result in losses totaling approximately $610 million, including impairment losses.
Source:Oct 9, 2026, 05:40 UTC
Terumo lowered its full-year operating profit forecast to ¥160 billion from ¥257.5 billion, projecting a 9.3% decline from the previous fiscal year, while leaving adjusted operating profit unchanged.
Source:Oct 9, 2026, 05:40 UTC
Terumo shares fell sharply.
Source:Oct 9, 2026, 00:15 UTC
Japanese ADRs were mixed but slightly higher, with Japan Post up 11.4% and Terumo down 9.3% among the listed movers.
Source:Oct 9, 2026, 00:10 UTC
Terumo shares weakened after the company revised its earnings outlook downward following the supply-contract termination agreement.
Source:Oct 8, 2026, 08:59 UTC
Terumo announced that it would terminate its plasma collection device supply contract with a subsidiary of CSL Limited, citing the unlikelihood of the planned device installation.
Oct 8, 2026, 07:30 UTC
Terumo lowered its forecast for net profit attributable to owners for the fiscal year ending March 2027 to ¥120.0 billion from ¥193.1 billion, projecting an 11.7% decline from the prior year’s ¥135.9 billion.
Source:Oct 2, 2026, 00:03 UTC
On October 2, 2026, AI Mech, WTI crude oil, SHIFT, MonotaRO, GO, and TISI were quoted at special buy indications on the Tokyo market, while Mitsubishi Corp, Kurasus, Marubeni, Terumo, Chugai Pharmaceutical, and M3 were quoted at special sell indications.
Source:Sep 30, 2026, 06:30 UTC
Terumo Neuro signed an agreement to acquire Arsenal Medical, adding the investigational NeoCast liquid embolic technology to its neurovascular portfolio.
Sep 12, 2026, 04:30 UTC
Hospiten Cabo San Lucas will host the 14th Unidos de Corazón medical mission from August 15 to 27, 2026, with volunteer teams performing 25 pediatric cardiovascular procedures for children from Baja California Sur.
Source:Sep 4, 2026, 09:23 UTC
Terumo held a briefing on its newly completed building at the Kofu Plant in Showa-cho, Yamanashi Prefecture, which will double the company's CDMO production capacity and is scheduled to start operations in 2027 as a core hub for supplying biopharmaceuticals domestically and internationally.
Source: